Replies to post #151484 on Biotech Values

[mcbio]

I think you forgot to mention that ARRY has applied for late-breaker status at the ACR next week in order to present the updated 797 trial regarding the identification of a biomarker for "disease-modification" in OA. No guarantee that they will get to present; the conference is just ten days away. The idea for 797 is for a "opiod-replacement therapy." Also, a reference was made to the fact that 797 showed some efficacy in the reiief of pain due to bone mets.

Also, Squarer made reference a couple of times to NVS' R&D day next week. Squarer implied that there should be some info on MEK-162.

Almost all of that info was in the earnings PR I posted before. I try to limit my CC notes to new info.